Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Open-Label Study of PTC923 (Sepiapterin) in Phenylketonuria

NCT05166161 is registered in ClinicalTrials.gov with PTC Therapeutics as lead sponsor.

NCT NCT05166161
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05166161 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Open-Label Study of PTC923 (Sepiapterin) in Phenylketonuria
Lead sponsor
PTC Therapeutics
Phase
Phase 3
Overall status
Completed
Start date
February 14, 2022
Completion date
July 21, 2026
Enrollment
247 (actual)
Sites
46

Conditions

As the registry lists them; a condition with its own page is linked.

phenylketonuria